You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀(01952.HK)終止與Immunomedics腫瘤藥物開發權 料錄收益最多逾3億美元
雲頂新耀-B(01952.HK)公布,與其全資附屬Everest Medicines II及Everest SG,和吉利德(GILD.US)的全資附屬Immunomedics訂立終止及過渡服務協議,以終止就Immunomedics向集團授出獨家許可權以於特定地區開發及商業化授權產品sacituzumab govitecan(TrodelvyTM),另向Immunomedics轉讓其與授權產品相關的全部知識產權、監管材料及其他資產,而Everest提供過渡服務,使Immunomedics或其聯屬公司能夠在有關地區開發及商業化授權產品。 公司指出,有關總代價最高約為4.55億美元,當中包括初始預付款2.8億美元及里程碑付款合共1.75億美元。所得款項淨額料最高約為4.51億美元,擬將30%用於撥支與公司主要業務一致的業務發展活動及拓展藥物管線;15%用於持續開發Nefecon;35%用於現有管線資產的餘下部分(Nefecon除外);10%用於增強發現能力;及10%用作營運資金及一般行政用途。該交易將產生的最高收益約為3.14億美元。 此外,公司認為交易將最大化授權產品價值及影響力,並可使公司專注於發展其他管線資產,同時尋求其他機會以透過業務發展及內部研發工作進一步拓展其藥物產品的現有管線。 Sacituzumab govitecan是一款同類首創的抗體藥物偶聯物,是一種在許多類型腫瘤(包括超過90%的乳腺癌和膀胱癌)中均過度表達的細胞表面抗原。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account